newsfilter
← Latest News
Business Wire·

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

-JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program,